Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.

被引：0
|
作者：
Xu, Chongrui
Tu, Hai-Yan
Sun, Yue-Li
Li, Yang-Si
Xu, Bing-Fei
Wang, Bin-Chao
Chen, Hua-Jun
Wang, Zhen
Zhou, Qing
Yang, Jin-Ji
Wu, Yi-Long
机构：
[1] South China Univ Technol, Sch Med, Guangdong Acad Med Sci, Guangdong Lung Canc Inst,Guangdong Prov Peoples H, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21670
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
    Tanvetyanon, Tawee
    Creelan, Benjamin C.
    Antonia, Scott J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 903 - 910
  • [32] Hepatitis B surface antigen-positive but DNA-negative patients
    Alter, MJ
    SEMINARS IN DIALYSIS, 2001, 14 (03) : 230 - 231
  • [33] Hepatitis B surface antigen-positive donor to negative recipient lung transplantation
    Belga, Sara
    Kabbani, Dima
    Doucette, Karen
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (08) : 2287 - 2288
  • [34] Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
    Besse, Benjamin
    Garrido, Pilar
    Puente, Javier
    Cortot, Alexis
    Eugenia Olmedo, Maria
    Perol, Maurice
    Gil, Maciej
    Chao, Grace
    Shahidi, Javad
    Bennouna, Jaafar
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S397 - S397
  • [35] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
  • [36] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Hellmann, M. D.
    Rizvi, N.
    Gettinger, S. N.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J.
    Shen, Y.
    Harbison, C. T.
    Nathan, F.
    Ready, N. E.
    Antonia, S. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
  • [37] Pembrolizumab for the treatment of non-small cell lung cancer
    Lim, Sung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 397 - 406
  • [38] The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC)
    Hofman, M.
    Agema, B. C.
    Degens, J.
    Hurkmans, D. P.
    Dumoulin, D. W.
    Schols, A.
    Koolen, S. L.
    Groeneveldt, C.
    Worp, W. V. D.
    Hendriks, L. E.
    Van der Leest, C. H.
    Aerts, J. G.
    Mathijssen, R. H.
    Dingemans, A-M. C.
    Langen, R.
    Bins, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S847 - S847
  • [39] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Nivolumab for treating non-small cell lung cancer
    Guibert, Nicolas
    Mazieres, Julien
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1789 - 1797
12345